FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361951573> ?p ?o ?g. }

• W4361951573 abstract "<div>Abstract<p><b>Purpose:</b> EGFR is frequently overexpressed in cervical cancer, suggesting EGFR blockade as a promising treatment approach. Cetuximab, an anti EGFR antibody, used conjointly with radiochemotherapy, was feasible in first-line treatment of cervix carcinoma limited to the pelvis.</p><p><b>Experimental Design:</b> This randomized phase II trial enrolled 78 FIGO stage IB2–IIIB cervical cancer patients to either cisplatin-based radiochemotherapy alone (arm B, <i>n</i> = 38) or conjointly with a 6-week course of weekly cetuximab (arm A, <i>n</i> = 40). Brachytherapy was given to the pelvic mass. Primary endpoint was disease-free survival (DFS) at 2 years. EGFR expression and targeted sequencing were performed in 54 of 78 patients.</p><p><b>Results:</b> Cetuximab over a 6-week period did not improve DFS at 24 months. At 31 months median follow-up, DFS was not significantly different (<i>P</i> = 0.18). Complete response at 4 to 6 months was strongly predictive for excellent DFS (log-rank test; <i>P</i> < 0.001). <i>PIK3CA, KRAS</i>, and <i>STK11</i> mutations were observed in 22%, 4%, and 2% of patients, respectively. No tumor with a <i>PI3K</i> pathway mutation showed complete response (0/8 in arm A and 0/6 in arm B), whereas 14 of 52 (27%) tumors without mutations did (<i>P</i> = 0.021). <i>PI3K</i> pathway-mutated tumors showed a trend toward poorer DFS (<i>P</i> = 0.06) following cetuximab (8/22) as compared with those following standard treatment only (6/18).</p><p><b>Conclusions:</b> Similar to patients with head and neck cancer, patients with cervical cancer showed no gain in DFS at 2 years following a combined treatment of cetuximab with radiochemotherapy. Although treatment tolerance and compliance were satisfactory, it remains to be demonstrated whether maintenance therapy with cetuximab could be beneficial in selected patient groups. <i>Clin Cancer Res; 21(11); 2530–7. ©2015 AACR</i>.</p></div>" @default.
• W4361951573 created "2023-04-05" @default.
• W4361951573 creator A5003470485 @default.
• W4361951573 creator A5006619822 @default.
• W4361951573 creator A5009939921 @default.
• W4361951573 creator A5014340300 @default.
• W4361951573 creator A5015945392 @default.
• W4361951573 creator A5019521580 @default.
• W4361951573 creator A5026180389 @default.
• W4361951573 creator A5028630369 @default.
• W4361951573 creator A5034951520 @default.
• W4361951573 creator A5037964830 @default.
• W4361951573 creator A5039569090 @default.
• W4361951573 creator A5042461515 @default.
• W4361951573 creator A5045188427 @default.
• W4361951573 creator A5045922787 @default.
• W4361951573 creator A5047459731 @default.
• W4361951573 creator A5048137285 @default.
• W4361951573 creator A5050982274 @default.
• W4361951573 creator A5053227325 @default.
• W4361951573 creator A5054899121 @default.
• W4361951573 creator A5055446776 @default.
• W4361951573 creator A5056961294 @default.
• W4361951573 creator A5067469764 @default.
• W4361951573 creator A5069166380 @default.
• W4361951573 creator A5069435488 @default.
• W4361951573 creator A5070962149 @default.
• W4361951573 creator A5072055304 @default.
• W4361951573 creator A5085149517 @default.
• W4361951573 creator A5085752463 @default.
• W4361951573 creator A5086083902 @default.
• W4361951573 creator A5088326833 @default.
• W4361951573 creator A5090374532 @default.
• W4361951573 creator A5091655083 @default.
• W4361951573 creator A5091820656 @default.
• W4361951573 date "2023-03-31" @default.
• W4361951573 modified "2023-10-18" @default.
• W4361951573 title "Data from <i>PIK3CA</i> Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients" @default.
• W4361951573 doi "https://doi.org/10.1158/1078-0432.c.6523898.v1" @default.
• W4361951573 hasPublicationYear "2023" @default.
• W4361951573 type Work @default.
• W4361951573 citedByCount "0" @default.
• W4361951573 crossrefType "posted-content" @default.
• W4361951573 hasAuthorship W4361951573A5003470485 @default.
• W4361951573 hasAuthorship W4361951573A5006619822 @default.
• W4361951573 hasAuthorship W4361951573A5009939921 @default.
• W4361951573 hasAuthorship W4361951573A5014340300 @default.
• W4361951573 hasAuthorship W4361951573A5015945392 @default.
• W4361951573 hasAuthorship W4361951573A5019521580 @default.
• W4361951573 hasAuthorship W4361951573A5026180389 @default.
• W4361951573 hasAuthorship W4361951573A5028630369 @default.
• W4361951573 hasAuthorship W4361951573A5034951520 @default.
• W4361951573 hasAuthorship W4361951573A5037964830 @default.
• W4361951573 hasAuthorship W4361951573A5039569090 @default.
• W4361951573 hasAuthorship W4361951573A5042461515 @default.
• W4361951573 hasAuthorship W4361951573A5045188427 @default.
• W4361951573 hasAuthorship W4361951573A5045922787 @default.
• W4361951573 hasAuthorship W4361951573A5047459731 @default.
• W4361951573 hasAuthorship W4361951573A5048137285 @default.
• W4361951573 hasAuthorship W4361951573A5050982274 @default.
• W4361951573 hasAuthorship W4361951573A5053227325 @default.
• W4361951573 hasAuthorship W4361951573A5054899121 @default.
• W4361951573 hasAuthorship W4361951573A5055446776 @default.
• W4361951573 hasAuthorship W4361951573A5056961294 @default.
• W4361951573 hasAuthorship W4361951573A5067469764 @default.
• W4361951573 hasAuthorship W4361951573A5069166380 @default.
• W4361951573 hasAuthorship W4361951573A5069435488 @default.
• W4361951573 hasAuthorship W4361951573A5070962149 @default.
• W4361951573 hasAuthorship W4361951573A5072055304 @default.
• W4361951573 hasAuthorship W4361951573A5085149517 @default.
• W4361951573 hasAuthorship W4361951573A5085752463 @default.
• W4361951573 hasAuthorship W4361951573A5086083902 @default.
• W4361951573 hasAuthorship W4361951573A5088326833 @default.
• W4361951573 hasAuthorship W4361951573A5090374532 @default.
• W4361951573 hasAuthorship W4361951573A5091655083 @default.
• W4361951573 hasAuthorship W4361951573A5091820656 @default.
• W4361951573 hasConcept C121608353 @default.
• W4361951573 hasConcept C126322002 @default.
• W4361951573 hasConcept C143998085 @default.
• W4361951573 hasConcept C2778220009 @default.
• W4361951573 hasConcept C2779998722 @default.
• W4361951573 hasConcept C2781187634 @default.
• W4361951573 hasConcept C526805850 @default.
• W4361951573 hasConcept C71924100 @default.
• W4361951573 hasConceptScore W4361951573C121608353 @default.
• W4361951573 hasConceptScore W4361951573C126322002 @default.
• W4361951573 hasConceptScore W4361951573C143998085 @default.
• W4361951573 hasConceptScore W4361951573C2778220009 @default.
• W4361951573 hasConceptScore W4361951573C2779998722 @default.
• W4361951573 hasConceptScore W4361951573C2781187634 @default.
• W4361951573 hasConceptScore W4361951573C526805850 @default.
• W4361951573 hasConceptScore W4361951573C71924100 @default.
• W4361951573 hasLocation W43619515731 @default.
• W4361951573 hasOpenAccess W4361951573 @default.
• W4361951573 hasPrimaryLocation W43619515731 @default.
• W4361951573 hasRelatedWork W2010163599 @default.
• W4361951573 hasRelatedWork W2049754458 @default.
• W4361951573 hasRelatedWork W2120490763 @default.
• W4361951573 hasRelatedWork W2313360580 @default.
• W4361951573 hasRelatedWork W2435704186 @default.

• next